The Trendlines Group Portfolio Company IBI Ag Raises $10 Million Series A Led by Corteva

- Trendlines holds an 11.2% stake in IBI AG, post series A funding round. The milestone underscores Trendlines' portfolio strength and innovation in impactful agrifood companies.
- Founded and incubated by Trendlines, IBI Ag has developed a pioneering nanobody-based bioinsecticide platform that adapts human therapeutic antibody technology for sustainable crop protection.
- The investment will accelerate product development and regulatory milestones, advancing next-generation biological pest control solutions toward commercialization.

Misgav, Israel – 12 November 2025 – The Trendlines Group Ltd. (SGX: 42T; OTCQX: TRNLY), an investment group focused on agrifood and medtech innovation, today announced that its portfolio company **IBI Ag,** in which the company has a stake of 11.2%, post series A funding round, has successfully completed a **$10 million Series A financing round**, led by **Corteva** through its Corteva Catalyst platform.

This final closing marks a significant step forward for IBI Ag, which was **founded and incubated by Trendlines**, and reflects growing international recognition of the company's breakthrough **nanobody-based bioinsecticide technology**. The round included participation from **The Trendlines Group**, **Iron Nation, Consensus Business Group, Bandera Capital, First Imagine Ventures**, and a grant from the **Israel Innovation Authority**.

"IBI Ag exemplifies our mission to advance technologies that address critical global challenges in food production." said Nitza Kardish, PhD, CEO, Trendlines Agrifood Fund; Vice Chair, Trendlines Agrifood Innovation Centre. "From inception at Trendlines to this successful Series A led by a global leader like Corteva, IBI Ag's journey demonstrates how our investment model can nurture disruptive innovation to commercial maturity."

IBI Ag's proprietary platform adapts single-domain antibody (nanobody) technology from human therapeutics to agriculture, enabling the development of precise, environmentally responsible bioinsecticides. This approach has the potential to transform pest management by protecting high-value crops while preserving beneficial insect species.

The investment will allow IBI Ag to accelerate product development and regulatory progress, advancing its next-generation biological pest control solutions toward global markets.
"IBI Ag's achievement is a strong validation of the quality and commercial potential within the Trendlines portfolio," added Haim Brosh, CEO of Trendlines. "We are proud to support companies

that not only deliver innovation but also create meaningful impact in sustainability and food security."

-The End-

About The Trendlines Group Ltd.
The Trendlines Group (SGX: 42T; OTCQX: TRNLY) invests in and develops innovations in agrifood and medtech, transforming early-stage technologies into impactful businesses. With operations in Israel and Singapore, Trendlines combines capital, expertise, and strategic partnerships to drive growth, advance global sustainability, and create long-term value for shareholders.

---

*This press release has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

Investor Contact Information
Israel:
Shira Zimmerman, The Trendlines Group
shira@trendlines.com
Tel: +972.72.260.7000

Singapore:
Kamal Samuel, Financial PR
kamal@financialpr.com.sg
Rishika Tiwari, Financial PR
rishika@financialpr.com.sg
Tel: +65.6438.2990